Navigation Links
Planet Technologies Announces Agreement to Acquire Antigen Laboratories

RIDGEFIELD, Conn. & LIBERTY, Mo., Sept. 4 /PRNewswire-FirstCall/ -- Planet Technologies, Inc. (Nasdaq: PLNT), a specialty pharmaceutical company whose current operations are focused on the marketing and sale of allergen avoidance products, and Antigen Laboratories, Inc. (Antigen), a privately-held FDA licensed manufacturer of allergenic extracts for immunotherapy, today announced that they entered into a definitive agreement under which Planet will acquire Antigen.

Under the agreement, Planet will acquire all of the outstanding equity of Antigen for $10 million, plus the payment of certain liabilities, contingent upon Planet procuring the required financing to complete the transaction.

"The acquisition of Antigen's allergenic extract immunotherapy business complements our existing allergen avoidance business. The Antigen transaction continues to deliver on our strategy to acquire and build specialty allergy businesses, focused on marketing to allergy-related physicians in the United States", said Ed Steube, Chief Executive Officer and President of Planet.

Planet's current, wholly owned operating subsidiary, Allergy Control Products, Inc. (ACP), is a leading supplier of physician-recommended allergen avoidance products to control indoor allergens. ACP markets its proprietary products, along with those of other suppliers, through physician office brochures, customer catalogs and its web site. ACP receives patient referrals from 4,000 physicians in the United States annually.

Antigen will operate as a wholly owned subsidiary of Planet. Physicians use Antigen's allergenic extracts for immunotherapy, which historically have been administered to patients in controlled doses by subcutaneous injections ("SCIT"). Antigen provides allergenic extracts to over 1,500 physicians in the United States annually.

"We are excited to work with the Planet team to develop substantial growth opportunities for immunotherapy in the U.S.", said Tom Willoughby, President at Antigen. Mr. Willoughby will continue as president of Antigen, as well as become Vice-Chairman of Planet's Board of Directors.

Planet believes that the base businesses of both ACP and Antigen will benefit from cross merchandising between each company's physician relationships. As such, the acquisition of Antigen is part of Planet's overall goal to build a specialty pharmaceutical company focused on asthma and allergy, implementing consolidation and cross merchandising activities within the allergy market.

Importantly, upon completion of the acquisition, the company intends to commence a sublingual immunotherapy ("SLIT") clinical development program. SLIT is the administration of immunotherapy through drops of allergenic extract being placed under the tongue, versus the traditional SCIT route of administration. It is a particularly attractive treatment alternative for young children, those at increased risk for SCIT (i.e. asthmatic persons), and those who cannot go to a physician's office once a week for an injection.

In European countries where SLIT has received regulatory approval, it has been reported that the availability of both SCIT and SLIT has greatly expanded the number of patients seeking immunotherapy. The company believes that an FDA-approved SLIT product also will expand the much larger U.S. market, as allergy-related physicians will have the enhanced option of offering either SCIT or SLIT based immunotherapy for their patients.

There are six competitors in the allergenic extract immunotherapy market within the U.S,

In addition to the $10 million acquisition price, Planet estimates it will need $10 million for transaction-related professional fees, payoff of debts, purchase of a building and funding of clinical trials, as well as other expenses related to the regulatory approval process.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Planet undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Planet's business.

SOURCE Planet Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Global Polio Eradication: A Campaign to Vaccinate Every Child on the Planet
2. Protecting Oceans is Important to Keeping Planet Cool
3. New green Pyre to Cool Planet While Burning Indias Dead
4. Work Less to Sustain Planet Earth, Say Activists
5. Worms are Killing the Planet
6. Researchers Develop Technologies to Devour Food Pathogens
7. Researchers Study Safety of Assisted Reproductive Technologies
8. India to Propose Global Fund for Clean Energy Technologies
9. PM announces a new health care order for India
10. PowderMed Announces Needle-Less Flu Vaccine
11. Ramdoss Announces Introduction of RCH-II
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... The recently published 32nd Annual Report ... reveals that in 2014, someone called a poison center about every 11 seconds. ... were human exposure cases. , The American Association of Poison Control Centers (AAPCC) ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... as their exclusive channel partner for the Nutraceutical Specialties products into oral solid ... US, effective immediately. , “We are pleased to announce our expanded distribution ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, ... Matrix Surgical Mesh technology for soft tissue repair in the US via Insightra’s ... long-term resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology: